Davis Mark Steven 4

What Happened
Mark Steven Davis, a director of Myriad Genetics, was granted 59,701 restricted stock units (RSUs) on June 4, 2026. The grant is reported at $0.00 per share (no cash paid) — total immediate value shown as $0 — and is recorded on an SEC Form 4 as an award (transaction code A).

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (next-day filing).
• Award: 59,701 RSUs; reported acquisition price $0.00 (grant); total immediate value $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: RSUs granted under the Issuer's 2026 Equity Incentive Plan. Each RSU converts to one share upon vesting. Vesting occurs on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders.

Context
RSU grants to directors are a common form of equity compensation and do not involve an out‑of‑pocket purchase. Because these units vest in the future, they do not represent immediately tradable shares unless vested and delivered. This filing reports an award (not a buy or sell) and was filed promptly the day after the grant.